---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-264493"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T06:05:35.248252+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences FB-401 Phase 2 atopic dermatitis trial misses primary endpoint EASI-50

## Summary
- Primary endpoint EASI-50: 58% active vs 60% placebo (p=0.7567), not statistically significant.
- Secondary endpoint EASI-90: 27.6% active vs 20.5% placebo (p=0.3075); IGA success: 38.2% vs 29.5% (p=0.2599).
- Company will not continue development of FB-401; plans to provide future update on company direction.
- Cash and cash equivalents of $50.8 million as of June 30, 2021.
- Previously scheduled September 7 conference call canceled.

## SEC filing metadata
- accession: 0001193125-21-264493
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312521264493/0001193125-21-264493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312521264493/d88078d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-264493
- JSON: https://secwatch.observer/filing/0001193125-21-264493.json
- Plain text: https://secwatch.observer/filing/0001193125-21-264493.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.